» Articles » PMID: 32038784

Association of the G134A and G184C Polymorphisms in the Gene with Lung Cancer Incidence

Overview
Journal Toxicol Res
Specialty Toxicology
Date 2020 Feb 11
PMID 32038784
Authors
Affiliations
Soon will be listed here.
Abstract

The G184C and G134A single nucleotide polymorphisms (SNPs) of the gene result in Ala62Pro and Gly45Asp substitutions, respectively. Here, we tested whether these SNPs are associated with an alteration in lung cancer incidence. We examined 80 Korean subjects with lung cancer and 240 age- and sex-matched controls. For each subject, the gene was PCR amplified and sequenced. We observed that the odds ratio (OR) for lung cancer was 3.37 higher in subjects with the G184C polymorphism than in controls (95% confidence interval (CI), 0.89~12.73, = 0.07). In contrast, the OR for lung cancer was 1.23 in subjects with the G134A polymorphism compared to controls (95% CI, 0.68~2.20, = 0.49). The G184C polymorphism exacerbated the effects of smoking on lung cancer development. Gene-smoking interaction analyses revealed that past or present smokers with the G184C polymorphism had a higher incidence of lung cancer (OR, 24.72; 95% CI, 4.48~136.31; < 0.01) than control smokers (OR, 6.65; 95% CI, 2.72~16.28; < 0.01). However, there was only a slight difference in the ORs for lung cancer between control smokers and smokers with the G134A polymorphism. These findings suggest that the G184C polymorphism, but not the G134A polymorphism, is associated with an increased risk of lung cancer.

References
1.
Sugimura H, Wakai K, Genka K, Nagura K, Igarashi H, Nagayama K . Association of Ile462Val (Exon 7) polymorphism of cytochrome P450 IA1 with lung cancer in the Asian population: further evidence from a case-control study in Okinawa. Cancer Epidemiol Biomarkers Prev. 1998; 7(5):413-7. View

2.
Chevalier D, Allorge D, Lo-Guidice J, Cauffiez C, Lhermitte M, Lafitte J . Detection of known and two novel (M331I and R464S) missense mutations in the human CYP1A1 gene in a French Caucasian population. Hum Mutat. 2001; 17(4):355. View

3.
Vineis P, Veglia F, Benhamou S, Butkiewicz D, Cascorbi I, Clapper M . CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls. Int J Cancer. 2003; 104(5):650-7. DOI: 10.1002/ijc.10995. View

4.
Solus J, Arietta B, Harris J, Sexton D, Steward J, McMunn C . Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics. 2004; 5(7):895-931. DOI: 10.1517/14622416.5.7.895. View

5.
Bartsch H, Nair U, Risch A, Rojas M, Wikman H, Alexandrov K . Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev. 2000; 9(1):3-28. View